Kinnevik AB (publ)

Key Holdings

The portfolio is entirely composed of Recursion Pharmaceuticals, Inc. (RXRX), a healthcare technology company. This position represents 100% of the portfolio’s value, totaling $65.56 million. Kinnevik holds 13.43 million shares of Recursion, indicating a substantial ownership stake that likely carries significant influence or strategic importance. The lack of any other holdings positions Recursion not just as an asset, but as the singular focus of Kinnevik’s reported public equity exposure. This suggests that Kinnevik views the company as a core long-term holding rather than a tactical trade, as they have chosen to maintain the position despite a 3.6% decline in value over the quarter without rebalancing or hedging with other assets.